

HOW TO ADAPT YOUR NEURODEGENERATIVE DISEASE TRIAL TO THE COVID-19 PANDEMIC

COVID-19 disrupted the world of clinical research. Get your trial on solid ground again with a constructive and practical evaluation of your operations and study execution tactics.

1 REWORK WHERE, HOW, WHEN, AND WHETHER VISITS TAKE PLACE



Review the study schedule to determine which visits and assessments can be done remotely or by third-party home visit vendors - including drug administration or delivery



Complete formal evaluations and risk assessments for new study locations to maintain quality and training



Build in flexibility wherever possible to accommodate continually changing circumstances and regulations

2 MAKE IT EASIER FOR PATIENTS TO JOIN - AND STAY IN - YOUR STUDY



Go digital for consent and screening whenever possible



Maintain regular telephone check-ups, home visits, or video sessions when face-to-face visits aren't feasible



Continue outreach to families to engage and build rapport with participant support networks

3 CREATIVELY PRESERVE NEUROIMAGING AND CLINICAL ASSESSMENT FIDELITY

Don't sacrifice quality of neuroimaging review - use centralized or remote raters when possible

Accept alternative file formats (such as jpg or pdf) to ensure receipt of imaging data, especially when visit sites or personnel change

Conduct neurological assessments via telephone, video, or home visits to avoid jeopardizing efficacy results

4 QUICKLY AND CLEARLY ENACT PROTOCOL CHANGES



Release formal, detailed guidance to study staff and patients after any changes to the protocol



Provide training on new processes or to new vendors as soon as possible



Perform frequent check-ins following protocol adjustments to answer questions and resolve any issues

5 CREATIVELY PRESERVE NEUROIMAGING AND CLINICAL ASSESSMENT FIDELITY



Teach study staff how to properly document all COVID-19-related data in the electronic data capture system



Determine how COVID-19 infection or symptoms will affect a patient's ability to participate



Reduce site burden for data acquisition or data entry by hiring a centralized third-party vendor

DON'T LET COVID-19 DERAIL YOUR NEURODEGENERATIVE DISEASE TRIAL

Build lasting resilience into your research program by making adjustments that will protect your trial from disruptions now and down the road. Nimble, responsive, thoughtful planning is crucial.

Learn more about adapting your neurodegenerative trial to the world of COVID-19:



Read our eBook for more tips



Read our white paper about our recent success with a 6,000-patient neurodegenerative disease trial



Reach out to one of our experts today to learn more about how to protect your study

When tough times hit, you need a partner with uncommon adaptability and expertise. Choose the Cure for the Common CRO.